๐Ÿ“œ Bankruptcy Creditor Rights โ€” Advisory Approval

Friday, May 15, 2026 ยท Internal review only ยท Voice: restructuring-grade (appellate-court fluent)
Today's Briefing Lead

The bankruptcy creditor-rights docket is doctrine-dense this week. Fourth Circuit's Cook opinion (Apr 27, 2026) narrows equitable mootness in Chapter 13 โ€” the cross-circuit drift on the doctrine is now the single most active battleground in confirmation appeals. Purdue plan went effective May 1, 2026 with first tranche payments flowing (cross-link Tab 06). SDNY Chapter 15 third-party-release ruling (May 2026, Mayer Brown) opens a comity-based workaround to Harrington v. Purdue Pharma. Highland Capital remand drafting and Serta S.D. Tex. trial (set Feb 2026, likely sliding) are the gating events of the next 60 days. Subchapter V threshold restoration bill (S. 3977) sits in Senate Judiciary. Watch: 4th Cir. en banc petition deadline; Red River Talc 5th Cir. oral-argument calendar; first batch of Boy Scouts Trust second-distributions.

Today's Advisory (collapsible)
Open full advisory
โ–ผ

Equitable mootness โ€” fresh 4th Circuit data point

Cook v. Chapter 13 Trustee, No. 25-1048 (4th Cir. Apr. 27, 2026). Just-issued published panel opinion limiting equitable mootness in a single-debtor Chapter 13 confirmation appeal. The court reversed a district-court dismissal that had treated post-confirmation payments and the entry of a successor plan as enough to moot the appeal. Held equitable mootness is a "narrow, pragmatic doctrine" โ€” not a routine shield in single-debtor consumer cases. Creates fresh tension with the Second Circuit's substantial-consummation presumption and reinforces the Fifth, Sixth, Eighth, Ninth, and Tenth Circuits' more restrictive approach. Petition for rehearing en banc is the next watchpoint; if denied, cert clock starts and a SCOTUS petition could land in late summer. NCBRC and Bernstein Burkley have written it up; National Law Review summary expected.

Third-party releases & exculpation โ€” Chapter 15 path emerging

SDNY Chapter 15 third-party-release ruling (May 2026, Mayer Brown). District court confirmed that nonconsensual third-party releases can survive Harrington v. Purdue Pharma when imposed in foreign restructuring proceedings recognized via Chapter 15 โ€” applying comity rather than Section 1129 to the release issue. Pillsbury and other restructuring practices are tracking this as a meaningful workaround to Purdue. The doctrinal implication: U.S. issuers with foreign-recognized restructurings may continue to obtain nonconsensual releases that would be foreclosed under a direct Section 1129 plan. Expect appeal to the Second Circuit. Delaware bankr. court (Dec 2025) separately rejected a broad gatekeeper provision citing Highland Capital and Purdue โ€” drafters cannot back-door exculpation through gatekeeper language. 9th Cir. v. 5th Cir. exculpation split continues to widen: Blixseth permits narrow exculpation for plan participants; Highland limits to estate fiduciaries only.

Texas Two-Step / Red River Talc on appeal

In re Red River Talc LLC (5th Cir.). J&J's third Texas Two-Step attempt was dismissed March 2025 (S.D. Tex.) for the same bad-faith-filing concerns that took down LTL Management Rounds 1 and 2. Appeal is now in the Fifth Circuit (S.D. Tex. venue). DOJ U.S. Trustee continues aggressive opposition to liability-management bankruptcy. Without a circuit-level published opinion endorsing divisional-merger structures on the merits, the practical playbook for mass-tort defendants now favors litigation settlement (3M's $6B AFFF approach) or aggregate-settlement in MDL โ€” not bankruptcy. Watch for an oral-argument calendar entry summer/fall 2026.

Purdue plan implementation

Purdue Pharma plan effective May 1, 2026 per Michigan AG implementation order. Initial tranche: ~$1.5B from Sacklers plus ~$900M from Purdue at effectiveness. Subsequent Sackler tranches scheduled $500M May 2027, $500M May 2028, $400M May 2029. April 29, 2026 NJ federal criminal sentencing of $5.5B cleared the path for dissolution and trust funding. Assets transfer to Knoa Pharma (new non-profit focused on opioid-treatment medicines). ProPublica and CNN Health are documenting victim documentation/exclusion gaps under the new framework. Cross-link Tab 06 (this is the same matter on the mega-class settlements list).

Watchlist (next 60 days)

Cook rehearing en banc petition in the 4th Cir. by mid-June. Red River Talc oral-argument calendar entry at the 5th Cir. Serta S.D. Tex. trial (set Feb 2026, likely slipping) โ€” if it proceeds, expect a damages judgment and a renewed appellate cycle; if it settles, the 5th Cir.'s interpretive holding stands as the law. S. 3977 Subchapter V threshold bill โ€” Senate Judiciary action; ABI backing. Boy Scouts Trust second-distribution rollout. PFAS/AFFF first personal-injury cohort โ€” mid-late 2026 expected payment start. SDNY Chapter 15 release ruling appeal โ€” watch for Second Circuit briefing schedule. Q2 2026 mega Chapter 11 filings โ€” Q1 commercial Ch. 11s up 42% YoY (Epiq May 6, 2026); healthcare up 33%.

Key Dates (next 60 days)
Cook v. Trustee rehearing en banc petition โ€” 4th Cir. deadline mid-June 2026.
Purdue Pharma plan effective โ€” May 1, 2026 (now in implementation). Cross-link Tab 06.
Red River Talc / J&J 5th Cir. oral-argument calendar entry โ€” expected summer/fall 2026.
Serta S.D. Tex. trial โ€” set Feb 2026; if proceeds, damages judgment + second appellate cycle.
S. 3977 Subchapter V threshold โ€” Senate Judiciary action; markup is reportable.
Boy Scouts Trust second-distribution rollout โ€” round-number thresholds reportable.
PFAS/AFFF first personal-injury cohort โ€” mid-late 2026 expected payment start.
SDNY Chapter 15 release ruling appeal โ€” watch for 2d Cir. briefing schedule.
Q2 2026 mega Ch. 11 filings โ€” Q1 commercial Ch. 11s up 42% YoY (Epiq May 6).
LinkedIn Post (proposed)
The bankruptcy creditor-rights docket is doctrine-dense this week. โ€ข Fourth Circuit's Cook v. Chapter 13 Trustee (Apr 27, 2026, published): equitable mootness narrowed sharply in single-debtor Chapter 13. The court called it a "narrow, pragmatic doctrine" โ€” not a routine post-confirmation shield. Cross-circuit drift is now severe. 2d Cir. retains its substantial-consummation presumption. 5th Cir. bypasses on the merits. 6th Cir. excludes Ch. 7. The cert vehicle is in sight. โ€ข SDNY Chapter 15 third-party-release ruling (May 2026): District court confirmed nonconsensual third-party releases survive Harrington v. Purdue Pharma when imposed in foreign restructurings recognized via Chapter 15 โ€” applying comity rather than Section 1129. This is the meaningful workaround to Purdue that practice has been watching for. Expect a Second Circuit appeal. โ€ข Delaware bankr. court (Dec 2025) rejected a broad gatekeeper provision citing Highland Capital and Purdue. Drafters can no longer back-door exculpation through gatekeeper language. โ€ข Purdue Pharma plan effective May 1. Knoa Pharma takes the assets. ~$2.4B in initial tranche payments now flowing. ProPublica documenting victim-exclusion gaps. โ€ข J&J's third Texas Two-Step (Red River Talc) is on appeal to the 5th Cir. The DOJ U.S. Trustee is aggressively opposed. Three consecutive J&J losses without a circuit decision endorsing divisional-merger filings on the merits means the practical playbook now favors litigation settlement (3M's $6B AFFF approach) โ€” not bankruptcy. Watch: Cook en banc petition; Red River Talc briefing schedule; SDNY Chapter 15 release-ruling appeal; Senate Judiciary action on S. 3977 (Subchapter V $7.5M restoration). #Bankruptcy #Chapter11 #Restructuring #CreditorRights #Confirmation #EquitableMootness #PurdueRelease
โœ“ Copied
Not legal advice. Voice grade: restructuring-grade (appellate-court fluent). Verify all docket and agency citations against primary sources before acting. Knowledge baseline at references/background.md.